Lercanidipine in patients with chronic renal failure: The ZAFRA study

Renal Failure

Volumn 27, Issue 1, 2005, Pages 73-80

  Robles, N R ^a   Ocon, J ^b   Gomez, C F ^c   Manjon, M ^d   Pastor, L ^e   Herrera, J ^f   Villatoro, J ^g   Calls, J ^h   Torrijos, J ^h   Rodriguez V I ⁱ   Rodriguez, M M A ^j   Mendez, M L ^k   Morey, A ^l   Martinez, F I ^m   Marco, J ⁿ   Liebana, A ^o   Rincon, B ^p   Tornero, F ^p  

^a HOSPITAL INFANTA CRISTINA   (Spain)

^b FUNDACIÓ PUIGVERT   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^e HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^f HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^g HOSPITAL GENERAL DE CASTELLÓN   (Spain)

^h HOSPITAL DE MANACOR   (Spain)

ⁱ HOSPITAL SEVERO OCHOA   (Spain)

^j HOSPITAL LA INMACULADA   (Spain)

^k HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^l Clinica Miramar   (Spain)

^m HOSPITAL DE GALDAKAO   (Spain)

ⁿ HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^o Hosp Univ Ciudad de Jaén   (Spain)

^p HOSPITAL VIRGEN DE LA LUZ   (Spain)

more..

Author keywords

Chronic renal failure; Hypertension; Lercanidipine

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIHYDROPYRIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LERCANIDIPINE;

ADULT; AGED; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD EXAMINATION; BLOOD PRESSURE REGULATION; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; HUMAN; HYPERTENSION; KIDNEY FUNCTION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RENAL PROTECTION; RISK ASSESSMENT; SIDE EFFECT; TREATMENT OUTCOME; URINALYSIS; VASODILATATION;

AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; FEMALE; HUMANS; HYPERTENSION; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 19944432489     PISSN: 0886022X     EISSN: None     Source Type: Journal    
DOI: 10.1081/JDI-42801     Document Type: Article

References (43)

1. Klag, M.J.; Whelton, P.K.; Randall, B.L.; Neaton, J.D.; Brancati, F.L.; Ford, C.E.; Shulman, N.B.; Stamler, J. Blood pressure and end-stage renal disease in men. N. Engl. J. Med. 1996, 334, 13-18.
2. Rostand, S.G.; Brunzell, J.D.; Cannon, R.O.; Victor, R.G. Cardiovascular complications in renal failure. J. Am. Soc. Nephrol. 1991, 2, 1053-1058.
3. Shulman, N.B.; Ford, C.E.; Hall, W.D.; Blaufox, M.D.; Simon, D.; Langford, H.G.; Schneider, K.A. Prognostic value of serum creatinine and effect of treatment of hypertension on renal function. Results from the hypertension detection and follow-up program. The hypertension detection and follow-up program cooperative group. Hypertension 1989, 13 (Suppl 5), I180-I193.
4. Samuelsson, O.; Wilhelmsen, L.; Elmfeldt, D.; Pennert, K.; Wedel, H.; Wikstrand, J.; Pennert, K.; Wedel, H.; Wikstrand, J.; Berglund, G. Predictors of cardiovascular morbidity in treated hypertension: results from the primary preventive trial in Göteborg, Sweden. J. Hypertens. 1985, 3, 167-176.
5. Ruilope, L.M.; Campo, C.; Rodriguez-Artalejo, F.; Lahera, V.; Garcia-Robles, R.; Rodicio, J.L. Blood pressure and renal function: therapeutic implications. J. Hypertens. 1996, 14, 1259-1263.
6. Mandhavan, S.; Stockwell, D.; Cohen, H.; Alderman, M.H. Renal function during antihypertensive treatment. Lancet 1995, 345, 749-751.
7. Barrios, V.; Navarro, A.; Esteras, A.; Luque, M.; Romero, J.; Tamargo, J.; Prieto, L.; Carrasco, J.L.; Herranz, I.; Navarro-Cid, J.; Ruilope, L.M. Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE study. Blood Pressure 2002, 11, 95-100.
8. Leonetti, G.; Magnani, B.; Pessina, A.C.; Rappelli, A.; Trimarco, B.; Zanchetti, A.; COHORT Study Group, Tolerability of long-term treatment with lercanidipine versus amlodipine and lacidipine in elderly hypertensives. Am. J. Hypertens. 2002, 15, 932-940.
9. DiGiorgio, L.A.; Orlandini, F.; Malasoma, P.; Zappa, A. A double-blind cross-over study of lercanidipine versus amlodipine in the treatment of mild-to-moderate essential hypertension. Curr. Ther. Res. 1999, 60, 511-520.
10. Tobbe, S.; Epstein, M. The use of calcium antagonists in the treatment of hypertensive persons with kidney disease. Curr. Hypertens. Rep. 2002, 4, 191-194.
11. Bitar, R.; Flores, O.; Reverte, M.; Lopez-Novoa, J.M.; Macias, J.F. Beneficial effect of verapamil added to chronic ACE inhibitor treatment on renal function in hypertensive elderly patients. Int. Urol. Nephrol. 2000, 32 (2), 165-169.
12. Messerli, F.H. Calcium antagonists in hypertension: from hemodynamics to outcomes. Am. J. Hypertens. 2002, 15 (Pt2), 94S-97S.
13. Neal, B.; MacMahon, S.; Chapman, N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Blood pressure lowering treatment trialists' collaboration. Lancet 2000, 356, 1955-1964.
14. Opie, L.H.; Schall, R. Evidence-based evaluation of calcium channel blocker for hypertension: equality of mortality and cardiovascular risk relative to conventional therapy. J. Am. Coll. Cardiol. 2002, 39, 315-322.
15. Lewis, E.; Huncksicker, L.G.; Clarke, W.R.; Berl, T.; Pons, M.A.; Lewis, J.B.; Ritz, E.; Atkins, R.C.; Rohde, R. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 2001, 345, 851-860.
16. Rengo, F.; Romis, L. Activity of lercanidipine in double-blind comparison with nitrendipine in combination treatment of patients with resistant essential hypertension. J. Cardiovasc. Pharmacol. 1997, 29 (Suppl. 2), S54-S58.
17. Morisco, C.; Trimarco, B. Efficacy and tolerability of lercanidipine in comparison to and in combination with atenolol in patients with mild to moderate essential hypertension in a double blind controlled study. J. Cardiovasc. Pharmacol. 1997, 29 (Suppl. 2), S54-S58.
18. Barbagallo, M.; Barbagallo, G. Sangiorgi, Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension. Aging Clin. Exp. Res. 2000, 12, 375-379.
19. Messerli, F.H. Vasodilatory edema: a common side effect of antihypertensive therapy. Am. J. Hypertens. 2001, 14, 978-979.
20. Hanson, L.; Lindholm, L.H.; Ekbom, T.; Dahlöf, B.; Lanke, J.; Schersten, B.; Wester, P.-O.; Hedner, T.; d Faire, U.; STOP-Hypertension-2 study group, Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity. The Swedish trial in old patients with hypertension-2 study. Lancet 1999, 354, 1751-1756.
21. Messerli, F.H.; Oparil, S.; Feng, Z. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonists (either nifedipine or amlodipine) versus high-dose calcium antagonists monotherapy for systemic hypertension. Am. J. Cardiol. 2000, 86, 1182-1187.
22. Parving, H.H. The impact of hypertension and antihypertensive treatment on the course and prognosis of diabetic nephropathy. J. Hypertens. 1990, 8, S187-S191.
23. Peterson, J.C.; Adler, S.; Burkart, J.M.; Greene, T.; Hebert, L.A.; Hunsicker, L.G.; King, A.; Klahr, S.; Massry, S.G.; Seifter, J.L. Blood pressure control, proteinuria and the progression of renal disease: the modification of diet in renal disease study. Ann. Intern. Med. 1995, 123, 754-762.
24. Toto, R.D.; Mitchell, N.C.; Smith, R.D. "Strict" blood pressure control and progression of renal disease in hypertensive nephrosclerosis. Kidney Int. 1995, 48, 851-859.
25. Gansevoort, R.T.; Sluiter, W.J.; Hemmelder, M.H.; de Zeeuw, D.; de Jong, P.E. Antiproteinuric effect of blood pressure lowering agents: a meta-analysis of comparative trials. Nephrol. Dial. Transplant. 1995, 10, 1963-1974.
26. Maki, D.D.; Ma, J.Z.; Louis, T.A.; Kasiske, B.L. Long-term effects of antihypertensive agents on proteinuria and renal function. Arch. Intern. Med. 1995, 155, 1073-1080.
27. Weidmann, P.; Schneider, M.; Bohlen, L. Therapeutic efficacy of different anti-hypertensive drugs in human diabetic nephropathy: an updated meta-analysis. Nephrol. Dial. Transplant. 1995, 10 (Suppl. 9), 39-45.
28. National High Blood Pressure Education Program Working Group on Hypertension and Renal Disease, 1995 Update of the working group reports on chronic renal failure and renovascular hypertension. Arch. Intern. Med. 1996, 156, 1938-1947.
29. Brenner, B.M.; Cooper, M.E.; de Zeeuw, D.; Keane, W.F.; Mitch, W.E.; Parving, H.H.; Remuzzi, G.; Snapinn, S.M.; Zhang, Z.; Shahinfar, S. Effect of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med. 2001, 345, 861-869.
30. Parving, H.H.; Lehnert, H.; Bröchner-Mortensen, J.; Gomis, R.; Andersen, S.; Arner, P. For the study group Irbesartan in patients with type 2 diabetes and microalbuminuria. N. Engl. J. Med. 2001, 345, 870-878.
31. Kesteloot, H.; Joossens, J.V. On the determinants of the creatinine clearance: a population study. J. Hum. Hypertens. 1996, 10, 245-249.
32. Lemann, J.; Bidani, A.; Bain, R.P.; Lewis, E.; Rohde, R.D.; Collaborative Study Group, Use of serum creatinine to estimate glomerular filtration rate in health and early diabetic nephropathy. Am. J. Kidney Dis. 1990, 16, 236-243.
33. Voyaki, S.M.; Staessen, J.A.; Thijs, L.; Wang, J.G.; Efstratopoulos, A.D.; Birkenhäger, W.H.; de Leeuw, P.W.; Leonetti, G.; Nachev, C.; Rodicio, J.L.; Tuomilehto, J.; Fagard, R.; Systolic Hypertension in Europe (Syst-Eur) Trial Investigators, Follow-up of renal function in treated and untreated older patients with isolated systolic hypertension. J. Hypertens. 2001, 19, 511-519.
34. Bakris, G.L.; Mangrum, A.; Copley, J.B.; Vicknair, N.; Sadler, R. Effect of calcium channel or β-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997, 29, 744-750.
35. Brown, M.J.; Palmer, C.R.; Castaigne, A.; de Leeuw, P.W.; Mancia, G.; Rosenthal, T.; Ruilope, L.M. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the international nifedipine GITS study: intervention as a goal in hypertension treatment (INSIGHT). Lancet 2000, 356, 366-372.
36. Agodoa, L.Y.; Appel, L.; Bakris, G.L.; Beck, G.; Bourgoignie, J.; Brigs, J.P.; Charlestown, J.; Cheek, D.; Cleaveland, W.; Douglas, J.G.; Douglas, M.; Dowie, D.; Faulkner, M.; Gabriel, A.; Gassman, J.; Greene, T.; Hall, Y.; Hebert, L.; Hiremath, L.; Jamerson, K.; Johnson, C.J.; Kopple, J.; Kusek, J.; Lash, J.; Lea, J.; Lewis, J.B.; Lip Kowitz, M.; Massry, S.; Middleton, J.; Miller, E.R., III.; Norris, K.; O'Conner, D.; Ojo, A.; Phillips, R.A.; Pogue, V.; Rahman, M.; Randall, O.S.; Rostand, S.; Schulmar, G.; Smith, W.; Thornley-Brown, D.; Tisher, C.C.; Toto, R.D.; Wright, J.T., Jr.; Xu, S. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001, 285, 2719-2728.
37. Epstein, M. Calcium antagonists and renal protection: emerging perspectives. J. Hypertens. 1998, 18 (Suppl. 4), S17-S25.
38. Sabbatini, M.; Leonardi, A.; Testa, R.; Vitaioli, L.; Amenta, F. Effect of calcium antagonists on glomerular arterioles in spontaneously hypertensive rats. Hypertension 2000, 35, 775-779.
39. Schultz, P.; Raij, L. Inhibition of human mesangial cell proliferation by calcium channel blockers. Hypertension 1990, 15 (Suppl. 1), 76-80.
40. Hebert, L.A.; Bain, R.P.; Verme, D.; Cattran, D.; Whittier, F.C.; Tolchin, N.; Rohde, R.D.; Lewis, E.J.; Collaborative Study Group, Remission of nephrotic range proteinuria in type I diabetes. Kidney Int. 1994, 46, 1688-1693.
41. Bakris, G.L.; Williams, B. ACE inhibitors and calcium antagonists alone or combined: is there a difference on progression of diabetic renal disease?. J. Hypertens. 1995, 13 (suppl 2), S95-S101.
42. Bakris, G.L.; Weir, M.R.; DeQuattro, V.; McMahon, F.G. Effects of an ACE inhibitor/calcium antagonists combination on proteinuria in diabetic nephropathy. Kidney Int. 1998, 54, 1283-1289.
43. The effects of an ACE inhibitor and a calcium antagonists on the progression of renal disease: the nephross study. Nephrol. Dial. Transplant. 2001, 16, 2158-2166.